Antabio is a France-based biopharmaceutical company dedicated to the discovery and development of first-in-class molecule compounds to treat severe infections caused by multi-drug resistant bacterial pathogens. Antabio uses its proprietary technology, world-class antibacterial discovery expertise and partnering-oriented business strategy to advance novel drugs that will offer solutions to the shortfall of the current antibacterial arsenal.
Pan Metallo Beta-Lactamase inhibitors
Treatment of complicated Gram-negative infections in hospitals
Disruptors of Pseudomonas biofilms
Treatment of chronic Pseudomonas infections (e.g. CF and COPD)